Table 1 

Increasing IgG titers to Lassa virus antigens through the vaccination schedule 

Immunogen 



Z+GPC VLP 
Z+GPC+NP VLP 

ELISA Ag 
naive 
pre 1^{st} boost 
pre 2^{nd }boost 
term. 
naive 
pre 1^{st} boost 
pre 2^{nd }boost 
term. 
p value 
VLP 
18 ± 17 
556 ± 975 
2667 ± 1058 
12800 ± 14311 
50 ± 0 
9920 ± 4637 
19520 ± 16963 
32000 ± 20239 
0.026 
sGP1 
< 10 
88 ± 69 
200 ± 254 
444 ± 384 ** 
< 10 
1520 ± 1159 
2480 ± 1159 
6800 ± 5215 
0.004 
GPCΔTM 
< 10 
95 ± 72 
215 ± 217 
700 ± 992 * 
< 10 
2960 ± 3657 
3440 ± 3478 
10400 ± 15179 
0.092 
NP 
< 10 
560 ± 310 
1220 ± 1060 
2000 ± 1265 



Endpoint ELISA titers for each timed point are mean ± SD, N = 10, except for starred entries, where * N = 9 and ** N = 8. The p value for terminal endpoint IgG titers generated against relevant LASV antigens between the two VLP formats is shown. Samples were collected on days 21 (pre1^{st }boost), 42 (pre2^{nd }boost) and 63 (term.) for titer analysis. 

Branco et al. Virology Journal 2010 7:279 doi:10.1186/1743422X7279 